Fractyl Health, Inc. Common Stock (GUTS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $11.99M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fractyl Health, Inc. Common Stock (GUTS) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Fractyl Health, Inc. Common Stock reported EPS of -$1.39, above the -$1.59 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GUTS's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
GUTS Earnings Call
The latest GUTS earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 11 quarters below that had an estimate, GUTS beat 8 and missed 3. The widest gap in the table came in the quarter ended Sep 30, 2025, when EPS landed 121.88% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$1.39 | -$1.59 | -$1.68 - -$1.38 | +12.58% | Beat | N/A | 4 | 0 up, 2 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.12 | -$0.15 | -$0.15 - -$0.11 | +20.00% | Beat | N/A | 6 | 3 up, 0 down | Aug 10, 2026 | N/A |
| Mar 31, 2026 | $0.06 | -$0.41 | N/A | +114.20% | Beat | N/A | 5 | 2 up, 1 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$0.07 | -$0.18 | -$0.22 - -$0.14 | +61.11% | Beat | N/A | 5 | 0 up, 2 down | Mar 24, 2026 | N/A |
| Sep 30, 2025 | -$0.71 | -$0.32 | -$0.38 - -$0.18 | -121.88% | Miss | N/A | 5 | 1 up, 0 down | Nov 12, 2025 | N/A |
| Jun 30, 2025 | -$0.57 | -$0.36 | -$0.38 - -$0.35 | -58.33% | Miss | N/A | 3 | 0 up, 1 down | Aug 12, 2025 | N/A |
| Mar 31, 2025 | -$0.49 | -$0.50 | -$0.53 - -$0.47 | +2.00% | Beat | N/A | 2 | 0 up, 0 down | May 13, 2025 | N/A |
| Dec 31, 2024 | -$0.52 | -$0.42 | -$0.53 - -$0.34 | -23.81% | Miss | N/A | 2 | 0 up, 1 down | Mar 3, 2025 | $3000 |
| Sep 30, 2024 | -$0.43 | -$0.50 | -$0.50 - -$0.50 | +14.00% | Beat | N/A | 1 | 0 up, 0 down | Nov 12, 2024 | $14000 |
| Jun 30, 2024 | -$0.36 | -$0.46 | N/A | +21.74% | Beat | N/A | N/A | N/A | Aug 14, 2024 | $43000 |
| Mar 31, 2024 | -$0.17 | -$0.30 | N/A | +43.33% | Beat | N/A | N/A | N/A | Apr 1, 2024 | $33000 |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$1.52 | N/A |
| Jun 30, 2026 | -$0.13 | N/A |
| Sep 30, 2025 | -$2.29 | N/A |
| Sep 30, 2024 | -$0.96 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,000 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,000 | 9 | |
| 2026Q2 | Jun 30, 2026 | 5,321 | 11 | |
| 2026Q1 | Mar 31, 2026 | 5,238 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,318 | 10 | |
| 2025Q3 | Sep 30, 2025 | 4,790 | 11 | |
| 2025Q2 | Jun 30, 2025 | 4,849 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,243 | 8 | |
| 2024Q4 | Dec 31, 2024 | 4,973 | 8 |
2026Q3 Earnings Call
Opening remarks
Brian Luque Head of Investor Relations and Corporate Development Thank you. This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer, and Lara Smith Weber, Chief Financial Officer. Before we begin, one change to our format: For the first time, we invited all of our shareholders to submit and vote on questions for management through Say by Robinhood. After our prepared remarks, I will read a selection of the most-voted shareholder questions, and then the operator will open the line to our covering analysts. Thank you to everyone who took part. During this call, we make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties and speak only as of the call's original date, and we undertake no obligation to update or revise any of these statements, even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Harith.
Harith Rajagopalan Chief Executive Officer Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing GLP-1s each month. Yet, of those who take GLP-1s, only 1 in 12 Americans remain on them for obesity at the end of 3 years. What happens for the 11 out of 12 who stop? On average, 85% of patients regain weight, and roughly two-thirds of the weight comes back within a year. That is a systemic pattern driven by biology, not an individual failure of willpower, and it doesn't have to be this way. So why does the weight come back? We believe the answer is in the gut. Modern unhealthy diets accelerate cellular aging in the gut. In plain terms, those changes make us more prone to obesity. And the aging gut may retain a metabolic memory that perpetuates disease. GLP-1 medicines have proven that dramatic weight loss is possible, but they neither reverse the underlying cellular aging causing obesity nor regenerate a healthy gut. They leave the underlying problem untouched. Revita aims to do both. It is designed to reset the gut's metabolic memory as a one-time outpatient procedure designed to ablate the damaged, unhealthy lining of the duodenum to allow healthier tissue to regenerate in its place. LASIK for obesity. It means the gut is now working with, not against, a patient's weight loss program.
Frequently Asked Questions About GUTS
Did GUTS beat earnings estimates last quarter?
Yes. Fractyl Health, Inc. Common Stock reported EPS of -$1.39 for the quarter ended Sep 30, 2026, above the -$1.59 estimate, a 12.58% surprise.
What EPS do analysts expect from GUTS next quarter?
The consensus EPS estimate for Fractyl Health, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$1.38 from 7 analysts, with estimates from -$1.76 to -$1.13.
How often does GUTS beat earnings estimates?
Fractyl Health, Inc. Common Stock beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +0.73%.
GUTS pages: Overview, Earnings, Forecast, Financials, Competitors